Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Role of Additional Novel Therapies in Myeloproliferative Neoplasms - p. 7 8. Acquired Uniparental Disomy in Myeloproliferative Neoplasms - p. 20 9. Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms - p. 26 10. Disordered Signaling in Myeloproliferative Neoplasms - p. 40 11. Role of Germline Genetic Factors in MPN Pathogenesis - p. 50 12. Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms - p. 58 13. Myeloproliferative Neoplasm Animal Models - p. 64 14. Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms - p. 73 15. Clinical Predictors of Outcome in MPN - p. 81 16. Systemic Mastocytosis - p. 91 17. Index - p. 98
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Role of Additional Novel Therapies in Myeloproliferative Neoplasms - p. 7 8. Acquired Uniparental Disomy in Myeloproliferative Neoplasms - p. 20 9. Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms - p. 26 10. Disordered Signaling in Myeloproliferative Neoplasms - p. 40 11. Role of Germline Genetic Factors in MPN Pathogenesis - p. 50 12. Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms - p. 58 13. Myeloproliferative Neoplasm Animal Models - p. 64 14. Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms - p. 73 15. Clinical Predictors of Outcome in MPN - p. 81 16. Systemic Mastocytosis - p. 91 17. Index - p. 98
